News
The Montes Claros site in Brazil is just one of many that Novo Nordisk has poured billions of dollars into as part of efforts ...
The Inflation Reduction Act (IRA) is expected to influence the clinical development strategies of pharma companies profoundly ...
US biotech Merida Biosciences has launched with $121m in Series A financing to develop therapeutics targeting disease-causing ...
Pharma CEOs have told EC President von der Leyen they may shift operations towards the US as trade tensions escalate.
US President Donald Trump has stated that the country is set to announce “major tariffs” on pharmaceutical imports very soon.
The EC has granted marketing authorisation for AbbVie's once-a-day treatment Rinvoq (upadacitinib) 15mg for adults with GCA.
The potential for cell and gene therapies is growing, offering groundbreaking treatments for rare genetic disorders and ...
With liver ailments on the rise, and obesity a key driver, understanding the treatment options available is critical.
Degrees has signed a patent licence agreement with Yale School of Medicine for tafenoquine development for babesiosis.
KalVista has licenced the commercialisation rights for sebetralstat, a hereditary angioedema (HAE) treatment, to Kaken in ...
Epsilogen has acquired antibody developer TigaTx in a deal that collates work from the companies’ alternative antibody ...
Eisai/Biogen’s Leqembi (lecanemab) was fully approved in the US in July 2023, and Eli Lilly’s Kisunla (donanemab) in July ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results